The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback